Translational Medicine Platform

Turning Basic Research into Better Patient Treatments

The Myelin Repair Foundation is changing the world of medical research, starting with developing a myelin repair therapeutic for multiple sclerosis (MS) faster than the status quo.

In order to drive its basic research and translate it into faster, more successful treatments for patients, the Myelin Repair Foundation has launched its Translational Medicine Platform (TMP). This platform is essential for developing a successful myelin repair treatment for MS, and will help revolutionize the entire world of medical research.

Translational medicine ensures discoveries move rapidly out of the lab and into the hands of patients in need, instead of lost in a black hole of scientific research called the Valley of Death.

Watch our video to see how the black hole of scientific research called the Valley of Death is preventing treatments from getting into the hands of patients, and why the Myelin Repair Foundation is working around the clock to fix this.

The Myelin Repair Foundation Translational Medicine Center (TMC)

To further advance myelin repair discoveries forward toward commercial development, the Myelin Repair Foundation recognized the importance of establishing a first-rate laboratory facility to support Myelin Repair Foundation's Translational Medicine Platform. Launched in the final quarter of 2011, the Myelin Repair Foundation’s Translational Medicine Center (TMC) is dedicated to the acceleration of the drug discovery process for new multiple sclerosis treatments. The Translational Medicine Center evaluates the most promising myelin research to transform basic scientific research into novel MS therapeutics.

By building upon the biological assays originally developed in Myelin Repair Foundation’s core academic labs, TMC will further optimize and share the myelination assays with Myelin Repair Foundation’s academic core labs and other biopharma company partners to accelerate MS drug discoveries. This state-of-the-art laboratory facility offers a rigorous, industry-leading translational medicine platform, led by Myelin Repair Foundation personnel with over four decades of extensive biopharma experience moving therapeutic compounds into clinical trials. The focus of the Myelin Repair Foundation Translation Medicine Center is the advancement of a wide range of novel myelin reparative therapeutics toward commercialization to benefit MS patients.

What Others are Saying

“If you just leave it to basic scientists working alone in their own labs, converting basic scientific discoveries into drugs almost never happens. Without the ARC model, there is no infrastructure for accelerating drug development.”

The content on this webpage is offered for informational purposes only. The information is not provided for the purpose of giving medical advice or recommending specific treatment options for any medical condition or health problem. You should never use the content of the webpage or any other information located on the website as a substitute for a thorough and complete discussion with your doctor about a medical condition or health problem you may have, and you should not rely on the materials in the websites when choosing a treatment plan or evaluating any other medical advice regarding any disease or medical condition. The Myelin Repair Foundation strongly urges you to consult one or more licensed physicians who are trained to diagnose and treat the symptoms of MS and other neurological diseases. The Myelin Repair Foundation makes no warranties whatsoever, express or implied, regarding the accuracy, completeness, timeliness, or usefulness of any information contained or referenced on the website. Health-related information and technology change frequently and therefore information contained in the website may be outdated, incomplete or incorrect. The Myelin Repair Foundation does not assume any risk whatsoever for your use of the information contained on the website and your use of the website and the materials contained herein is at your own risk.